Cometriq FDA Approval History
FDA Approved: Yes (First approved November 29, 2012)
Brand name: Cometriq
Generic name: cabozantinib
Dosage form: Capsules
Company: Exelixis, Inc.
Treatment for: Thyroid Cancer
Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Development Timeline for Cometriq
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.